



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/673,528	09/29/2003	Lixiao Wang	S63.2-6533-US04	1834
499 7590 05/10/2011 VIDAS, ARRETT & STEINKRAUS, P.A. SUITE 400, 6640 SHADY OAK ROAD EDEN PRAIRIE, MN 55344				
EXAMINER				
MATTHEWS, WILLIAM H				
ART UNIT		PAPER NUMBER		
3774				
MAIL DATE		DELIVERY MODE		
05/10/2011		PAPER		

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

# Office Action Summary

**Application No.**

10/673,528

**Applicant(s)**

WANG, LIXIAO

**Examiner**

William H. Matthews (Howie)

**Art Unit**

3774

**Period for Reply** -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 11 April 2011.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1 and 91-98, 100-116, 119-135 is/are pending in the application.
- 4a) Of the above claim(s) 102-104 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1 and 91-98, 100-101, 105-116, 119-135 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
  - ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO/SB/08)  
Paper No(s)/Mail Date 4/11/11 4/12/11
- 4) ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date: \_\_\_\_\_
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: \_\_\_\_\_

## **DETAILED ACTION**

### ***Response to Arguments***

Applicant's arguments with respect to claims 1,91-98,100-101,105-116,119-123 and new claims 124-135 have been considered but are moot in view of the new grounds of rejection set forth below.

### ***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1,91,92,94,96-101,108-111,113,115-116,119-120,124-128,130-135 are rejected under 35 U.S.C. 103(a) as being unpatentable over Scott et al. USPN 5383928 ("Scott") in view of Myers et al. USPN 5700285 ("Myers"), Richter USPN 5807404 ("Richter"), Wallsten et al. USPN 5061275 ("Wallsten"), and Applicant's admission at page 4 lines 1-5 or paragraph 0015 of the published application.

Scott disclose a balloon expandable metal stent comprising a sleeve coating of a polymer/drug mixture which may be placed on one stent end such that the middle is free of any polymer/drug (column 6 lines 41-45). The coating may include an RGD peptide

containing compound, a plurality of drugs, and plurality of polymers which is interpreted by examiner to meet the limitations of a plurality of different layers.

Scott is silent as to the stent comprising end cells which are larger or more flexible than the middle cells (claims 1,108,109,124, and 134). Each of Richter and Wallsten teach stent patterns comprising larger and more flexible end cells in order to provide an even expansion diameter to reduce likelihood of thrombosis or puncturing the vessel wall. It would have been obvious to one of ordinary skill in the art at the time of the invention to modify the stent pattern of Scott to include the varying cell sizes and flexibility taught in each of Richter and Wallsten in order to provide a safer expansion shape.

Scott is silent as to the stent comprising self expanding nickel titanium or stainless steel (claims 101,120,124,134). However, Applicant admits at page 4 lines 1-5 (or para [0015] of the published application) that stents of the self expanding and balloon expandable type are well known in the art. Examiner further takes Official Notice that nickel titanium alloys and stainless steel materials were well known in the stent art at the time of the invention. Thus it would have been obvious to one of ordinary skill in the art at the time of the invention to modify the stent materials of Scott to use self expanding nickel titanium or stainless steel in order to utilize known materials and expansion techniques to secure the stent in a blood vessel.

Scott is silent as to directly adhering the sleeve coating material to the metal surface of the stent. Myers teach stents with sleeve coatings wherein the material may be affixed to the stent by thermoplastic adhesive and the coatings remained intact after

collapsing and enlarging the stent (see abstract and examples). Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention to modify the stent in Scott to include adhesion points, as taught in Myers, to secure the sleeve position and prevent migration of the sleeve from the stent.

Regarding claim 126, the "at least one end" is readable on the distal or proximal end.

Regarding claim 127, the edges of the frame taught by Richter above may be square or triangular which comprise edges and would be covered by the sleeve of Scott.

Regarding claims 128,130,133, and 135, see Scott example at column 8 whereby a layer of EVA and layer of PTFE are disposed on a stent.

Claims 1,91-98,100-101,105-116,119-134 are rejected under 35 U.S.C. 103(a) as being unpatentable over Berg et al. USPN 5464650 ("Berg") in view of Scott et al. 5383928 ("Scott"), Nolting et al. USPN 6488701 ("Nolting"), Jang US PUB 2004/0106985 ("Jang"), Richter USPN 5807404 ("Richter"), Wallsten et al. USPN 5061275 ("Wallsten"), Applicant's admission at page 4 lines 1-5 or paragraph 0015 of the published application, and Kunz et al. US PUB 20020086896 ("Kunz").

Berg disclose self expanding or stainless steel, balloon expandable (claims 100-101,119-120) stents (c3:28-50) comprising a coating of a polymer and drug, wherein the coating is applied in a plurality of layers of the same coating material (claims 92,93,111-112,114-115,128-129). The coating adheres to the stent struts, and expands with the

stent, so is thus considered a bioadhesive, gel-like, and having apertures/perforations as broadly claimed (claims 91,95,96,110).

Regarding claims 1, 108, 109, 132 and 134, Berg is silent as to providing the coating on an end portion and not on a middle portion of the stent. Each of Scott and Nolting teach coated stents for delivering drugs to the blood vessel or vessel lumen wherein the drug delivery coating is placed only on an end portion of the stent in order to provide a targeted localized delivery. See Nolting col. 7:50-57 and Scott col. 5:26-33 and c6:41-45. Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention to modify the drug delivery stent of Berg to include the coating at only one or both end portions, as taught by Scott and Nolting, in order to provide a targeted delivery of therapeutic agents.

Berg disclose the stent may take the form of any stent design (column 3 lines 28-35) such as Palmaz 4800882 which includes cells but is silent as to the stent comprising end cells which are larger and more flexible than the middle cells (claims 1,108,109,124, and 134). Each of Richter and Wallsten teach stent patterns comprising larger and more flexible end cells in order to provide an even expansion diameter over the length of the stent to reduce likelihood of thrombosis or puncturing the vessel wall. It would have been obvious to one of ordinary skill in the art at the time of the invention to modify the stent pattern of Berg to include the varying cell sizes and flexibility taught in each of Richter and Wallsten in order to provide a safer expansion shape.

Berg is silent as to the self expanding stent comprising nickel titanium material (claims 124,134). However, Applicant admits at page 4 lines 1-5 (or para [0015] of the

published application) that stents of the self expanding and balloon expandable type are well known in the art. Examiner further takes Official Notice that nickel titanium alloys were well known self expanding materials in the stent art at the time of the invention. Thus it would have been obvious to one of ordinary skill in the art at the time of the invention to modify the stent materials of Berg to use nickel titanium material in order to utilize known materials to self expand the stent in a blood vessel.

Regarding claims 94, 113, and 130, Berg is silent as to providing a plurality of coating layers having different coating materials. Scott teach at lines 4-5 of col. 6 that plurality of layers may comprise different materials in order to achieve a desired release profile. Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention to modify the drug delivery stent of Berg to include a plurality of layers having different materials, as taught by Scott, in order to achieve a desired release profile.

Regarding claims 97, 105-107, 116, and 121-123, Berg is silent as to specifically using drugs such as RGD peptide containing compounds, tranilast, trapidil, or probucol. Berg do disclose the drug used may be one of a plethora of drug classes at col. 2 lines 55-62. Jang teaches at paragraphs [0344-0346] an expandable stent comprising therapeutic compounds which may include anti proliferative agents, inhibitors of vasoactive mechanisms inflammatory actions, or RGD peptide containing compounds in order to promote endothelialization. Tranilast, Trapidil, and ProbucoI are known therapeutic inhibitors or anti-proliferative agents in the art. Therefore it would have been obvious to one of ordinary skill in the art at the time the invention was made to

modify the stent disclosed by Berg, and modified by Nolting or Scott, to include RGD peptide containing compounds, Tranilast, Tropicidil, or Probucol, as taught by Jang '985, in order to promote endothelialization.

Regarding claim 127, Berg disclose the stent may take the form of Palmaz 4800882 which includes edges (Figures 2A-2B).

Regarding claim 133, Berg as modified above is silent as to using PTFE polymeric coverings. Kunz teach at paragraph 0173 stents comprising PTFE coverings for delivery of drugs. It would have been obvious to one of ordinary skill in the art at the time of the invention to use PTFE for the polymeric covering material, as taught by Kunz, with the Berg stent in order to utilize known covering materials to deliver a therapeutic agent from a stent.

### ***Conclusion***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to William H. Matthews (Howie) whose telephone number is 571-272-4753. The examiner can normally be reached on Monday-Friday 10-6:30PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, David J. Isabella can be reached on 571-272-4749. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.



Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/William H. Matthews/  
Primary Examiner  
Art Unit 3774